Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

891
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
891
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

63
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
63
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drug Delivery: Overview01:16

Drug Delivery: Overview

1.0K
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
1.0K
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

113
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Correction: Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats.

Journal of materials chemistry. B·2026
Same author

A single intra-articular injection of IDO-Gal3 shifts synovial fluid metabolic profiles for up to six weeks in male rats with knee instability.

Biochimie·2026
Same author

Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats.

Journal of materials chemistry. B·2026
Same author

Indoleamine 2,3-dioxygenase-galectin-3 fusion protein remodels inflammatory and fibrotic programs, ameliorating imiquimod-induced psoriasis.

npj biomedical innovations·2025
Same author

Engineering an indoleamine 2,3-dioxygenase immunotherapy <i>via</i> selective cysteine-to-serine mutations.

Molecular systems design & engineering·2025

Related Experiment Video

Updated: Mar 2, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

602

Combinatorial drug delivery approaches for immunomodulation.

Joshua M Stewart1, Benjamin G Keselowsky2

  • 1J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.

Advanced Drug Delivery Reviews
|May 24, 2017
PubMed
Summary

Combinatorial immunotherapy using engineered biomaterials offers a promising strategy to overcome limitations of single-drug treatments for immune diseases. This approach enhances immune responses and reduces side effects for better treatment outcomes.

Keywords:
AutoimmunityBiomaterialsCancerCombination therapyDrug deliveryImmunomodulationImmunotherapy

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

10.2K

Related Experiment Videos

Last Updated: Mar 2, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

602
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

10.2K

Area of Science:

  • Immunology
  • Biomaterials Science
  • Drug Delivery

Background:

  • Immunotherapy has advanced significantly, with some drugs replacing chemotherapy for immune-associated diseases.
  • However, single-agent immunotherapies often show incomplete efficacy due to complex disease pathology and limited mechanistic understanding.
  • Monotherapies struggle to achieve complete disease remission.

Purpose of the Study:

  • To review recent advancements in immunotherapy, focusing on combinatorial approaches.
  • To highlight novel drug delivery strategies using engineered biomaterials for immunotherapy.
  • To discuss future directions in immunomodulatory drug delivery.

Main Methods:

  • Review of current literature on immunotherapy and drug delivery systems.
  • Analysis of combinatorial immunotherapy strategies.
  • Exploration of engineered biomaterials for localized immunotherapy.

Main Results:

  • Combinatorial immunotherapy shows potential for treating complex immune pathologies by targeting multiple pathways.
  • Engineered biomaterials can localize immunotherapy, enhancing desired immune responses and minimizing toxicity.
  • Recent advances demonstrate the feasibility of these combined approaches.

Conclusions:

  • Targeting multiple immune pathways simultaneously is crucial for effective treatment of complex immune diseases.
  • Engineered biomaterials offer a powerful platform for localized and effective immunomodulatory drug delivery.
  • Future research should focus on exploiting these approaches for improved therapeutic outcomes.